Aligos Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapeutics for liver and viral diseases. The company targets unmet medical needs in areas such as chronic hepatitis B, metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH), and coronavirus infections. Its pipeline includes ALG-000184, a capsid assembly modulator for chronic hepatitis B; ALG-055009, an oral thyroid hormone receptor beta agonist for MASH; ALG-125755, a siRNA candidate for chronic hepatitis B; and ALG-097558 for COVID-19. Aligos Therapeutics Inc. leverages expertise in medicinal chemistry and biology to create purpose-built drugs with enhanced pharmacologic properties. The company engages in collaborations with partners like Merck, Emory University, and others to advance research, licensing, and commercialization efforts in oligonucleotides and protease inhibitors. Operating in the healthcare technology sector, it addresses hepatologic diseases and viral infections through targeted therapies against viral nucleic acids, encoded proteins, and related pathways. Founded in 2018 and headquartered in South San Francisco, California, Aligos Therapeutics Inc. plays a key role in advancing treatments for significant patient populations in virology and hepatology.